Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Novo Nordisk plans study of oral semaglutide in obesity

pharmatimesApril 23, 2021

Tag: Novo Nordisk , Semaglutide , obesity

PharmaSources Customer Service